CoChat

Oncogenic NRAS, Required for Pathogenesis of Embryonic Rhabdomyosarcoma, Relies upon the HMGA2–IGF2BP2 Pathway

Open access
Li, Zhizhong, Zhang, Yunyu, Ramanujan, Krishnan, Ma, Yan, Kirsch, David G., Glass, David J. · 2013 · Cancer Research

Published version of a preprint

Cited by 61

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Embryonic rhabdomyosarcoma (ERMS) is the most common soft-tissue tumor in children. Here, we report the identification of the minor groove DNA-binding factor high mobility group AT-hook 2 (HMGA2) as a driver of ERMS development. HMGA2 was highly expressed in normal myoblasts and ERMS cells, where its expression was essential to maintain cell proliferation, survival in vitro, and tumor outgrowth in vivo. Mechanistic investigations revealed that upregulation of the insulin–like growth factor (IGF) mRNA-binding protein IGF2BP2 was critical for HMGA2 action. In particular, IGF2BP2 was essential for mRNA and protein stability of NRAS, a frequently mutated gene in ERMS. shRNA-mediated attenuation of NRAS or pharmacologic inhibition of the MAP–ERK kinase (MEK)/extracellular signal-regulated kinase (ERK) effector pathway showed that NRAS and NRAS-mediated signaling was required for tumor maintenance. Taken together, these findings implicate the HMGA2–IGFBP2–NRAS signaling pathway as a critical oncogenic driver in ERMS. Cancer Res; 73(10); 3041–50. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-12-3947

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 32

  1. Bizer, 1980, Rhabdomyosarcoma, Am J Surg, 140, 687, 10.1016/0002-9610(80)90059-8 · doi:10.1016/0002-9610(80)90059-8
  2. Davicioni, 2009, Molecular classification of rhabdomyosarcoma—genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group, Am J Pathol, 174, 550, 10.2353/ajpath.2009.080631 · DOI · Paper page
  3. Xia, 2002, Molecular pathogenesis of rhabdomyosarcoma, Cancer Biol Ther, 1, 97, 10.4161/cbt.51 · DOI · Paper page
  4. Martinelli, 2009, RAS signaling dysregulation in human embryonal rhabdomyosarcoma, Genes Chromosomes Cancer, 48, 975, 10.1002/gcc.20702 · DOI
  5. Rubin, 2011, Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma, Cancer cell, 19, 177, 10.1016/j.ccr.2010.12.023 · DOI · Paper page
  6. Zhou, 1998, HMGI family proteins: architectural transcription factors in mammalian development and cancer, Keio J Med, 47, 73, 10.2302/kjm.47.73 · DOI
  7. Cleynen, 2008, The HMGA proteins: a myriad of functions (Review), Int J Oncol, 32, 289
  8. Fedele, 2006, HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity, Cancer Cell, 9, 459, 10.1016/j.ccr.2006.04.024 · DOI · Paper page
  9. Mayr, 2007, Disrupting the pairing between let-7 and HMGA2 enhances oncogenic transformation, Science, 315, 1576, 10.1126/science.1137999 · DOI · Paper page
  10. Lee, 2007, The tumor suppressor microRNA let-7 represses the HMGA2 oncogene, Genes Dev, 21, 1025, 10.1101/gad.1540407 · DOI · Paper page
  11. Watanabe, 2009, HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells, Am J Pathol, 174, 854, 10.2353/ajpath.2009.080523 · DOI · Paper page
  12. Fedele, 2010, HMGA and cancer, Biochim Biophys Acta, 1799, 48, 10.1016/j.bbagrm.2009.11.007 · DOI
  13. Thuault, 2008, HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition, J Biol Chem, 283, 33437, 10.1074/jbc.M802016200 · DOI · Paper page
  14. Li, 2011, High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis, Mol Cell Biol, 31, 2605, 10.1128/MCB.05447-11 · DOI · Paper page
  15. Brants, 2004, Differential regulation of the insulin-like growth factor II mRNA-binding protein genes by architectural transcription factor HMGA2, FEBS Lett, 569, 277, 10.1016/j.febslet.2004.05.075 · DOI · Paper page
  16. Christiansen, 2009, IGF2 mRNA-binding protein 2: biological function and putative role in type 2 diabetes, J Mol Endocrinol, 43, 187, 10.1677/JME-09-0016 · DOI · Paper page
  17. Nielsen, 2003, Nuclear transit of human zipcode-binding protein IMP1, Biochem J, 376, 383, 10.1042/bj20030943 · DOI
  18. Schaeffer, 2012, RNA-binding protein IGF2BP2/IMP2 is required for laminin-beta2 mRNA translation and is modulated by glucose concentration, Am J Physiol Renal Physiol, 303, F75, 10.1152/ajprenal.00185.2012 · DOI · Paper page
  19. Leeds, 1997, Developmental regulation of CRD-BP, an RNA-binding protein that stabilizes c-myc mRNA in vitro, Oncogene, 14, 1279, 10.1038/sj.onc.1201093 · DOI
  20. Schaaf, 2010, Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene, Cancer Res, 70, 762, 10.1158/0008-5472.CAN-09-2532 · DOI
  21. Stratton, 1989, Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction, Cancer Res, 49, 6324
  22. Paulson, 2011, High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis, Genes Chromosomes Cancer, 50, 397, 10.1002/gcc.20864 · DOI
  23. Johnson, 2005, RAS is regulated by the let-7 microRNA family, Cell, 120, 635, 10.1016/j.cell.2005.01.014 · DOI · Paper page
  24. Liu, 2010, MicroRNA-214 promotes myogenic differentiation by facilitating exit from mitosis via down-regulation of proto-oncogene N-ras, J Biol Chem, 285, 26599, 10.1074/jbc.M110.115824 · doi:10.1074/jbc.m110.115824
  25. Sharma, 2007, Oncogene addiction: setting the stage for molecularly targeted cancer therapy, Genes Dev, 21, 3214, 10.1101/gad.1609907 · DOI · Paper page
  26. Li, 2012, An HMGA2–IGF2BP2 axis regulates myoblast proliferation and myogenesis, Dev Cell, 23, 1176, 10.1016/j.devcel.2012.10.019 · DOI · Paper page
  27. Cleynen, 2007, HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in cooperation with nuclear factor-kappaB, Mol Cancer Res, 5, 363, 10.1158/1541-7786.MCR-06-0331 · DOI · Paper page
  28. Himoto, 2005, Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma, Int J Oncol, 26, 311
  29. Zhang, 2011, IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas, Am J Surg Pathol, 35, 868, 10.1097/PAS.0b013e318219c6f9 · DOI · Paper page
  30. Janiszewska, 2012, Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells, Genes Dev, 26, 1926, 10.1101/gad.188292.112 · DOI · Paper page
  31. Kelleher, 2012, Targeting NRAS in melanoma, Cancer J, 18, 132, 10.1097/PPO.0b013e31824ba4df · DOI
  32. Jaiswal, 2009, Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors, PLoS ONE, 4, e5717, 10.1371/journal.pone.0005717 · DOI · Paper page

Cited by

See all 61

Metadata

Authors
Li, Z., Zhang, Y., Ramanujan, K., Ma, Y., Kirsch, D. G., & Glass, D. J.
Venue
Cancer Research
Published
2013-05-12
Volume
73
Issue
10
Pages
3041-3050
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2147874293
Cited by
61
References
4
FWCI
5.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oncogenic NRAS, Required for Pathogenesis of Embryonic Rhabdomyosarcoma, Relies upon the HMGA2–IGF2BP2 Pathway. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-3947
The paper
Li, Z., Zhang, Y., Ramanujan, K., Ma, Y., Kirsch, D. G., & Glass, D. J. (2013). Oncogenic NRAS, Required for Pathogenesis of Embryonic Rhabdomyosarcoma, Relies upon the HMGA2–IGF2BP2 Pathway. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-3947

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.